Contract Pharma Manufacturing News

  1. BioCryst Announces European Licensing Agreement With Irish Affiliate Of Neopharmed Gentili For Navenibart In Hereditary Angioedema 5/4/2026

    BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that it entered into a license agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema (HAE) in Europe.

  2. HAS Group Announces Strategic Investments In Biodelphis Therapeutics 5/4/2026

    HAS Healthcare Advanced Synthesis and Biodelphis Therapeutics today announced the signing of a strategic agreement to support the development and GMP manufacturing of Antibody Protease Inhibitor Conjugates, an emerging class of targeted therapeutics designed to selectively inhibit disease‑driving proteases.

  3. Novelty Nobility Taps AGC Biologics To Further Develop Bispecific Drug Candidate 5/3/2026

    Novelty Nobility, a clinical-stage biotech company based in South Korea, expanded its manufacturing agreement with AGC Biologics, your friendly CDMO expert, to advance their bispecific antibody drug candidate through process development and GMP manufacturing at AGC Biologics’ facility in Chiba, Japan.

  4. Halo Pharma Emerges As Standalone CDMO Following Siegfried Acquisition Of Noramco 5/1/2026

    Halo Pharma (the “Company”), a leading CDMO partner to the pharmaceutical industry and previous division of Noramco Group, is now operating as a standalone business following Siegfried’s acquisition of Noramco Group’s small molecule API assets.

  5. KM Biologics Co. Ltd. Enters Into A Technology Collaboration With Serum Institute Of India 4/30/2026

    Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) hereby announces that KM Biologics Co., Ltd., a group company of Meiji Seika Pharma, has entered into a technology collaboration with Serum Institute of India Private Limited (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer, for the development and manufacturing of a Japanese encephalitis vaccine, and has achieved the first milestone under this collaboration.

  6. Huahui Health And BeOne Medicines Enter Into A Global Exclusive Option, License And Collaboration Agreement For Innovative Oncology Drug HH160 4/30/2026

    Huahui Health today announced that it has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a novel trispecific antibody in oncology immunotherapy. Under the agreement, BeOne Medicines is granted an exclusive option covering the development, manufacturing, and commercialization of HH160 worldwide.

  7. Rockwell Automation And Cytiva Launch Platform To Accelerate Digital Transformation For Biopharma Companies 4/29/2026

    Rockwell Automation, Inc., the world’s largest company dedicated to industrial automation and digital transformation, and Cytiva, a Danaher company and a leader in the life sciences industry, are jointly launching the Figurate Supervisory Control and Data Acquisition (SCADA) system designed to remove digital bottlenecks during biopharmaceutical manufacturing.

  8. Thermo Fisher Scientific Expands Plainville Facility With Flagship Bioprocess Design Center To Advance Biologics Development 4/29/2026

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its flagship U.S. Bioprocess Design Center (BDC) at the company’s Plainville, Mass., site, expanding the facility to support customers in developing and scaling biologics.

  9. Kytopen, T-CURX, And The Fraunhofer IZI Establish Center Of Excellence To Develop Advanced, Non-Viral Cell Therapies 4/29/2026

    Kytopen Corp., a leader in non-viral, continuous flow cellular engineering technologies, T-CURX GmbH ("T-CURX"), a leader in transposon-based CAR-T manufacturing, and Fraunhofer IZI, a developer of novel, clinically-relevant cellular therapies, today announced the establishment of a center of excellence (CoE).

  10. Candel Therapeutics Announces Commercialization Agreement With EVERSANA To Support Potential U.S. Launch Of Aglatimagene Besadenovec In Localized Prostate Cancer 4/29/2026

    Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced that it entered into a product commercialization agreement (the “Agreement”) with EVERSANA®, a leading provider of global commercialization services to the life sciences industry, to support the potential U.S. commercial launch of aglatimagene besadenovec (aglatimagene or CAN-2409) for the treatment of intermediate- to high-risk, localized prostate cancer.